We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.15 | -4.35% | 3.30 | 3.20 | 3.40 | 3.45 | 3.25 | 3.45 | 607,805 | 16:13:31 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.26 | 2.98M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/9/2020 19:38 | If the impending results are good, we've still then got to go to phase 3 before we can go to market with the product ? Hence still a year or two away perhaps ? | bigman786 | |
24/9/2020 19:04 | Worth laying out why this could be huge for PYC and arguably maybe even bigger and better for PYC than for VAL! 1. PYC have a FREE carried interest. We won't have to meet future costs of VAL201 (or VAL overheads) i.e. Trials costs/share dilution of Phase II/Phase III 2. Any VAL success in demonstrating SRC Inhibition approach may mean PYC can sell their SRC Inhibition modelling and simulation skills to other Companies looking to follow similar approach (maybe outside of Prostate Cancer as contract with VAL may have included a non-compete clause) 3. I believe Physiomics deliberately mentioned VAL201 in their August tweet because VAL have already approached them with regards to potentially engaging PYC to do modelling and simulation work on any future Phase II/III trial either for optimal dosing or potential combinations with potential Partner drugs? Proactive : "ValiRx teams up with Physiomics to accelerate the development of anti-cancer compound" www.proactiveinvesto | the stigologist | |
24/9/2020 19:04 | Worth laying out why this could be huge for PYC and arguably maybe even bigger and better for PYC than for VAL! 1. PYC have a FREE carried interest. We won't have to meet future costs of VAL201 (or VAL overheads) i.e. Trials costs/share dilution of Phase II/Phase III 2. Any VAL success in demonstrating SRC Inhibition approach may mean PYC can sell their SRC Inhibition modelling and simulation skills to other Companies looking to follow similar approach (maybe outside of Prostate Cancer as contract with VAL may have included a non-compete clause) 3. I believe Physiomics deliberately mentioned VAL201 in their August tweet because VAL have already approached them with regards to potentially engaging PYC to do modelling and simulation work on any future Phase II/III trial either for optimal dosing or potential combinations with potential Partner drugs? Proactive : "ValiRx teams up with Physiomics to accelerate the development of anti-cancer compound" www.proactiveinvesto | the stigologist | |
24/9/2020 18:51 | Can I also get an add to the other board pls | moizz | |
24/9/2020 18:14 | Can some one add me to the other board please . | reidy66 | |
24/9/2020 16:43 | 200k sell from this morning, must have spent the afternoon spec'ing their 911 | jusjusjus | |
24/9/2020 16:31 | A nice 62p UT trade will do. | 412069 | |
24/9/2020 16:29 | It would be good to hold at or above 60p going into Friday, totally insane week here so far GLA | tburns | |
24/9/2020 16:12 | Bring on monday | justtrying1 | |
24/9/2020 16:07 | Friday RNS are always regarded as trying to hide bad results | glasswala | |
24/9/2020 16:05 | I think the rns will land tomorrow with val201 results | justtrying1 | |
24/9/2020 16:02 | Have sold. I was getting a nose bleed. Now feel smug like being on the leaders board but sitting in the Club house with others finishing their 3rd round. But will now watch and wait to see if and when to jump in again. | acropolis1728 | |
24/9/2020 16:01 | SpreadEx gone telephone only, difficulty in sourcing stock | jusjusjus | |
24/9/2020 15:59 | Have been buying and selling since may2020. Made a big amount with avct and gdr, and ncyt. Cashed all in and now spreading around the covid plays again today. Have litterally bought around £200k of various stocks today. Cnt believe got the opp again on some of then | justtrying1 | |
24/9/2020 15:57 | very difficult to buy!!!!!!!!!!! | fission453 | |
24/9/2020 15:56 | building a nice position jt! | jusjusjus | |
24/9/2020 15:54 | Another 50k added | justtrying1 | |
24/9/2020 15:24 | 64.5p close 😉 | shares188 | |
24/9/2020 15:14 | it's been a manic 3 days, we should allow the share price a little slack to recover some strength, poor thing must be exhausted, 20% is more than enough to ask of it today. have a good night's rest sp, wake up lively and ready for action tomorrow, it's a Friday after all! | jusjusjus | |
24/9/2020 14:48 | Maybe more like 65, good volume agin | robertreece88 | |
24/9/2020 14:33 | I took the 80k earlier | justtrying1 | |
24/9/2020 14:27 | Early afternoon breather.... 70p today? | stumbleupon | |
24/9/2020 14:04 | Pyc is a dog stock and will always be just a p&d | chesty1 | |
24/9/2020 13:15 | Physiomics Plc is up DYOR | jasonpugh | |
24/9/2020 13:04 | Worth laying out why this could be huge for PYC and arguably maybe even bigger and better for PYC than for VAL! 1. PYC have a FREE carried interest. We won't have to meet future costs of VAL201 (or VAL overheads) i.e. Trials costs/share dilution of Phase II/Phase III 2. Any VAL success in demonstrating SRC Inhibition approach may mean PYC can sell their SRC Inhibition modelling and simulation skills to other Companies looking to follow similar approach (maybe outside of Prostate Cancer as contract with VAL may have included a non-compete clause) 3. I believe Physiomics deliberately mentioned VAL201 in their August tweet because VAL have already approached them with regards to potentially engaging PYC to do modelling and simulation work on any future Phase II/III trial either for optimal dosing or potential combinations with potential Partner drugs? | the stigologist |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions